TY - JOUR
T1 - Past, Current, and Future of Immunotherapies for Prostate Cancer
AU - Boettcher, Adeline N.
AU - Usman, Ahmed
AU - Morgans, Alicia
AU - VanderWeele, David J.
AU - Sosman, Jeffrey
AU - Wu, Jennifer D.
N1 - Funding Information:
Funding. NIH-NCI grant 1R01CA208246, 1R01CA204021, and R01CA212409 (to JW); by the Department of Defense?Prostate Cancer Research Program award W81XWH-15-1-0406 and W81XWH-17-1-0642 (to JW); and NIC/NCI Prostate Cancer SPORE P50 CA180995.
Publisher Copyright:
© Copyright © 2019 Boettcher, Usman, Morgans, VanderWeele, Sosman and Wu.
PY - 2019/9/11
Y1 - 2019/9/11
N2 - Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate cancer (mCRPC), of which there are limited treatment options available. Immunotherapy has presented substantial benefits for many types of cancer, but only a marginal benefit for mCRPC, at least in part, due to the immunosuppressive tumor microenvironment (TME). Current clinical trials are investigating monotherapies or combination therapies involving adoptive cellular therapy, viral, DNA vaccines, oncolytic viruses, and immune checkpoint inhibitors (ICI). Immunotherapies are also being combined with chemotherapy, radiation, and AST. Additionally, preclinical investigations show promise with the recent description of alternative ways to circumvent the immunosuppressive nature of the prostate tumor microenvironment, including harnessing the immune stimulatory NKG2D pathway, inhibiting myeloid derived suppressor cells, and utilizing immunomodulatory oncolytic viruses. Herein we provide an overview of recent preclinical and clinical developments in cancer immunotherapies and discuss the perspectives for future immunotherapies in PCa.
AB - Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate cancer (mCRPC), of which there are limited treatment options available. Immunotherapy has presented substantial benefits for many types of cancer, but only a marginal benefit for mCRPC, at least in part, due to the immunosuppressive tumor microenvironment (TME). Current clinical trials are investigating monotherapies or combination therapies involving adoptive cellular therapy, viral, DNA vaccines, oncolytic viruses, and immune checkpoint inhibitors (ICI). Immunotherapies are also being combined with chemotherapy, radiation, and AST. Additionally, preclinical investigations show promise with the recent description of alternative ways to circumvent the immunosuppressive nature of the prostate tumor microenvironment, including harnessing the immune stimulatory NKG2D pathway, inhibiting myeloid derived suppressor cells, and utilizing immunomodulatory oncolytic viruses. Herein we provide an overview of recent preclinical and clinical developments in cancer immunotherapies and discuss the perspectives for future immunotherapies in PCa.
KW - combination therapy
KW - immune checkpoint inhibitor
KW - immunotherapy
KW - metastatic-castration resistant prostate cancer
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85073004165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073004165&partnerID=8YFLogxK
U2 - 10.3389/fonc.2019.00884
DO - 10.3389/fonc.2019.00884
M3 - Review article
C2 - 31572678
AN - SCOPUS:85073004165
SN - 2234-943X
VL - 9
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 884
ER -